Increasing evidence that the risks of rhAPC may outweigh its benefits.
Eichacker
Peter Q
PQ
Natanson
Charles
C
D000890:Anti-Infective Agents / Q000009:adverse effects*; D064420:Drug-Related Side Effects and Adverse Reactions; D006470:Hemorrhage / Q000139:chemically induced* / Q000453:epidemiology; D017052:Hospital Mortality; D006801:Humans; D015994:Incidence; D007262:Infusions, Intravenous; D011486:Protein C / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000009:adverse effects; D018570:Risk Assessment; D018805:Sepsis / Q000188:drug therapy* / Q000401:mortality
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated